Abstract
After an early report that patients treated with angiotensin-converting enzyme (ACE) inhibitors had a lower than expected incidence of cancers, there was a large number of publications investigating the possible pathophysiological mechanism mediating this effect, as well as population studies comparing the incidence of cancers in patients treated with agents inhibiting the renin-angiotensin system with their incidence in the general population. Several mechanisms are proposed to explain a potential anti-tumour activity of such agents in vitro in experimental animal models. However, the population studies are mostly inconclusive, although they do suggest a possible interaction between ACE genotypes and susceptibility to altered behaviour of certain tumours.
MeSH terms
-
Angiotensin II Type 1 Receptor Blockers / pharmacology
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Animals
-
Anticarcinogenic Agents / pharmacology
-
Anticarcinogenic Agents / therapeutic use*
-
Antihypertensive Agents / pharmacology
-
Antihypertensive Agents / therapeutic use*
-
Cell Transformation, Neoplastic / drug effects
-
Cell Transformation, Neoplastic / metabolism
-
Evidence-Based Medicine
-
Humans
-
Hypertension / drug therapy*
-
Hypertension / enzymology
-
Neoplasms / enzymology
-
Neoplasms / prevention & control*
-
Renin-Angiotensin System / drug effects*
-
Signal Transduction / drug effects
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Anticarcinogenic Agents
-
Antihypertensive Agents